Additionally, Celest and Senti Bio have the option to expand clinical development of SN301A to Hong Kong, Macau and Taiwan. Senti Bio will retain all development and commercialization rights outside ...

Dan G. Duda, DMD, Ph.D., of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at ...

Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.

Hepatocellular carcinoma (HCC) is a significant global health issue, ranking as the sixth most prevalent malignancy and the ...

MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas ...

Importantly, hepatocellular carcinoma (HCC), the most common form of liver cancer, is now the fifth leading cause of cancer-related deaths in the United States and is projected to rise to the third by ...

Dan G. Duda, DMD, PhD, of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General Hospital, is the corresponding author of a paper published in ...

Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment ...

Dan G. Duda, DMD, PhD, of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General Hospital ...

Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (the “Company” or “Hepion”), a clinical stage biopharmaceutical company that had ...

Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...

The patient, diagnosed with a large hepatocellular carcinoma in the right lobe of the liver, faced significant challenges due ...